Inactive Instrument

Press Releases GTx, Inc. Nasdaq

Equities

US40052B1089

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	Apr. 18	AQ
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer	Mar. 15	AQ
Oncternal Therapeutics: Q4 Earnings Snapshot	Mar. 07	AQ
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results	Mar. 07	AQ
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results	Feb. 29	AQ
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	AQ
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	Feb. 01	AQ
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	Jan. 08	AQ
Oncternal Therapeutics Announces Reverse Stock Split	Jan. 04	AQ
Oncternal Therapeutics Reports Inducement Award under Nasdaq Listing Rule 5635(4)	Jan. 03	AQ
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	Jan. 02	AQ
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma	Dec. 26	AQ
Oncternal Therapeutics: Q3 Earnings Snapshot	Nov. 09	AQ
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results	Nov. 09	AQ
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results	Nov. 02	AQ
Penny Stock Momentum Watchlist (SING, CDIX, PXMD, ONCT)	23-10-27	AQ
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board	23-10-26	AQ
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer	23-10-26	AQ
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board	23-10-25	AQ
Oncternal Therapeutics : Corporate Presentation, October 2023	23-10-10	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases GTx, Inc. Nasdaq

Equities

US40052B1089

Press Releases

Filters